All Title Author
Keywords Abstract

PLOS ONE  2013 

Endothelial Transmigration by Trypanosoma cruzi

DOI: 10.1371/journal.pone.0081187

Full-Text   Cite this paper   Add to My Lib


Chagas heart disease, the leading cause of heart failure in Latin America, results from infection with the parasite Trypanosoma cruzi. Although T. cruzi disseminates intravascularly, how the parasite contends with the endothelial barrier to escape the bloodstream and infect tissues has not been described. Understanding the interaction between T. cruzi and the vascular endothelium, likely a key step in parasite dissemination, could inform future therapies to interrupt disease pathogenesis. We adapted systems useful in the study of leukocyte transmigration to investigate both the occurrence of parasite transmigration and its determinants in vitro. Here we provide the first evidence that T. cruzi can rapidly migrate across endothelial cells by a mechanism that is distinct from productive infection and does not disrupt monolayer integrity or alter permeability. Our results show that this process is facilitated by a known modulator of cellular infection and vascular permeability, bradykinin, and can be augmented by the chemokine CCL2. These represent novel findings in our understanding of parasite dissemination, and may help identify new therapeutic strategies to limit the dissemination of the parasite.


[1]  Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR (2008) The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis 2: e300.
[2]  Moncayo A, Silveira AC (2009) Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 104 Suppl 117–30.
[3]  Coura JR, Dias JC (2009) Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery. Mem Inst Oswaldo Cruz 104 Suppl 131–40.
[4]  Zhang L, Tarleton RL (1999) Parasite persistence correlates with disease severity and localization in chronic Chagas' disease. J Infect Dis 180: 480–486.
[5]  Tonelli RR, Giordano RJ, Barbu EM, Torrecilhas AC, Kobayashi GS, et al. (2010) Role of the gp85/trans-sialidases in Trypanosoma cruzi tissue tropism: preferential binding of a conserved peptide motif to the vasculature in vivo. PLoS Negl Trop Dis 4: e864.
[6]  Machado FS, Tyler KM, Brant F, Esper L, Teixeira MM, et al. (2012) Pathogenesis of Chagas disease: time to move on. Front Biosci (Elite Ed) 4: 1743–1758.
[7]  Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO (2012) Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol 9: 576–589.
[8]  Biolo A, Ribeiro AL, Clausell N (2010) Chagas cardiomyopathy—where do we stand after a hundred years? Prog Cardiovasc Dis 52: 300–316.
[9]  Muratore CA, Baranchuk A (2010) Current and emerging therapeutic options for the treatment of chronic Chagasic cardiomyopathy. Vasc Health Risk Manag 6: 593–601.
[10]  Apt W (2010) Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther 4: 243–253.
[11]  Barrias ES, de Carvalho TM, De Souza W (2013) Trypanosoma cruzi: Entry into Mammalian Host Cells and Parasitophorous Vacuole Formation. Front Immunol 4: 186.
[12]  de Melo-Jorge M, PereiraPerrin M (2007) The Chagas' disease parasite Trypanosoma cruzi exploits nerve growth factor receptor TrkA to infect mammalian hosts. Cell Host Microbe 1: 251–261.
[13]  Andrade D, Serra R, Svensjo E, Lima AP, Ramos ES Jr, et al. (2012) Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy. Br J Pharmacol 165: 1333–1347.
[14]  Rachid MA, Camargos ER, Barcellos L, Marques CA, Chiari E, et al. (2006) Blockade of endothelin ET(A)/ET(B) receptors favors a role for endothelin during acute Trypanosoma cruzi infection in rats. Microbes Infect 8: 2113–2119.
[15]  Villalta F, Scharfstein J, Ashton AW, Tyler KM, Guan F, et al. (2009) Perspectives on the Trypanosoma cruzi-host cell receptor interactions. Parasitol Res 104: 1251–1260.
[16]  Aridgides D, Salvador R, PereiraPerrin M (2013) Trypanosoma cruzi highjacks TrkC to enter cardiomyocytes and cardiac fibroblasts while exploiting TrkA for cardioprotection against oxidative stress. Cell Microbiol 15: 1357–1366.
[17]  Mukherjee S, Sadekar N, Ashton AW, Huang H, Spray DC, et al. (2013) Identification of a functional prostanoid-like receptor in the protozoan parasite, Trypanosoma cruzi. Parasitol Res 112: 1417–1425.
[18]  Machado FS, Dutra WO, Esper L, Gollob KJ, Teixeira MM, et al. (2012) Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease. Semin Immunopathol 34: 753–770.
[19]  Machado FS, Souto JT, Rossi MA, Esper L, Tanowitz HB, et al. (2008) Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytes. Microbes Infect 10: 1558–1566.
[20]  Talvani A, Teixeira MM (2011) Inflammation and Chagas disease some mechanisms and relevance. Adv Parasitol 76: 171–194.
[21]  Yamauchi LM, Aliberti JC, Baruffi MD, Portela RW, Rossi MA, et al. (2007) The binding of CCL2 to the surface of Trypanosoma cruzi induces chemo-attraction and morphogenesis. Microbes Infect 9: 111–118.
[22]  Caradonna KL, Burleigh BA (2011) Mechanisms of host cell invasion by Trypanosoma cruzi. Advances in parasitology 76: 33–61.
[23]  Epting CL, Coates BM, Engman DM (2010) Molecular mechanisms of host cell invasion by Trypanosoma cruzi. Experimental parasitology 126: 283–291.
[24]  Prado CM, Jelicks LA, Weiss LM, Factor SM, Tanowitz HB, et al. (2011) The vasculature in Chagas disease. Adv Parasitol 76: 83–99.
[25]  Komarova YA, Mehta D, Malik AB (2007) Dual regulation of endothelial junctional permeability. Sci STKE 2007: re8.
[26]  Vestweber D (2012) Relevance of endothelial junctions in leukocyte extravasation and vascular permeability. Ann N Y Acad Sci 1257: 184–192.
[27]  Komarova Y, Malik AB (2010) Regulation of endothelial permeability via paracellular and transcellular transport pathways. Annual review of physiology 72: 463–493.
[28]  Muller WA (2009) Mechanisms of transendothelial migration of leukocytes. Circ Res 105: 223–230.
[29]  Petri B, Bixel MG (2006) Molecular events during leukocyte diapedesis. FEBS J 273: 4399–4407.
[30]  Sage PT, Carman CV (2009) Settings and mechanisms for trans-cellular diapedesis. Front Biosci 14: 5066–5083.
[31]  Edwards AM, Massey RC (2011) How does Staphylococcus aureus escape the bloodstream? Trends Microbiol 19: 184–190.
[32]  Lemichez E, Lecuit M, Nassif X, Bourdoulous S (2010) Breaking the wall: targeting of the endothelium by pathogenic bacteria. Nat Rev Microbiol 8: 93–104.
[33]  Hyland KV, Asfaw SH, Olson CL, Daniels MD, Engman DM (2008) Bioluminescent imaging of Trypanosoma cruzi infection. Int J Parasitol 38: 1391–1400.
[34]  Schuster JP, Schaub GA (2000) Trypanosoma cruzi: skin-penetration kinetics of vector-derived metacyclic trypomastigotes. Int J Parasitol 30: 1475–1479.
[35]  Todorov AG, Andrade D, Pesquero JB, Araujo RdC, Bader M, et al. (2003) Trypanosoma cruzi induces edematogenic responses in mice and invades cardiomyocytes and endothelial cells in vitro by activating distinct kinin receptor (B1/B2) subtypes. The FASEB Journal 17: 73–75.
[36]  Del Nery E, Juliano MA, Lima AP, Scharfstein J, Juliano L (1997) Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi. J Biol Chem 272: 25713–25718.
[37]  Scharfstein J, Schmitz V, Morandi V, Capella MM, Lima AP, et al. (2000) Host cell invasion by Trypanosoma cruzi is potentiated by activation of bradykinin B(2) receptors. J Exp Med 192: 1289–1300.
[38]  Bossi F, Peerschke EI, Ghebrehiwet B, Tedesco F (2011) Cross-talk between the complement and the kinin system in vascular permeability. Immunol Lett 140: 7–13.
[39]  Orsenigo F, Giampietro C, Ferrari A, Corada M, Galaup A, et al. (2012) Phosphorylation of VE-cadherin is modulated by haemodynamic forces and contributes to the regulation of vascular permeability in vivo. Nat Commun 3: 1208.
[40]  Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA (2002) CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 3: 143–150.
[41]  Sullivan DP, Seidman MA, Muller WA (2013) Poliovirus receptor (CD155) regulates a step in transendothelial migration between PECAM and CD99. Am J Pathol 182: 1031–1042.
[42]  Muller WA, Ratti CM, McDonnell SL, Cohn ZA (1989) A human endothelial cell-restricted, externally disposed plasmalemmal protein enriched in intercellular junctions. J Exp Med 170: 399–414.
[43]  Muller WA, Luscinskas FW (2008) Assays of transendothelial migration in vitro. Methods Enzymol 443: 155–176.
[44]  Hyland KV, Leon JS, Daniels MD, Giafis N, Woods LM, et al. (2007) Modulation of autoimmunity by treatment of an infectious disease. Infection and immunity 75: 3641–3650.
[45]  Wirtz E, Leal S, Ochatt C, Cross GA (1999) A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99: 89–101.
[46]  Hirumi H, Hirumi K (1994) Axenic culture of African trypanosome bloodstream forms. Parasitology today (Personal ed) 10: 80–84.
[47]  Chang KP (1980) Human cutaneous lieshmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 209: 1240–1242.
[48]  Mamdouh Z, Chen X, Pierini LM, Maxfield FR, Muller WA (2003) Targeted recycling of PECAM from endothelial surface-connected compartments during diapedesis. Nature 421: 748–753.
[49]  Alcaide P, Newton G, Auerbach S, Sehrawat S, Mayadas TN, et al. (2008) p120-Catenin regulates leukocyte transmigration through an effect on VE-cadherin phosphorylation. Blood 112: 2770–2779.
[50]  Carman CV, Sage PT, Sciuto TE, de la Fuente MA, Geha RS, et al. (2007) Transcellular diapedesis is initiated by invasive podosomes. Immunity 26: 784–797.
[51]  Mamdouh Z, Mikhailov A, Muller WA (2009) Transcellular migration of leukocytes is mediated by the endothelial lateral border recycling compartment. J Exp Med 206: 2795–2808.
[52]  Andrade LO, Andrews NW (2005) The Trypanosoma cruzi-host-cell interplay: location, invasion, retention. Nat Rev Microbiol 3: 819–823.
[53]  Barr SC, Han W, Andrews NW, Lopez JW, Ball BA, et al. (1996) A factor from Trypanosoma cruzi induces repetitive cytosolic free Ca2+ transients in isolated primary canine cardiac myocytes. Infect Immun 64: 1770–1777.
[54]  Andrade LO, Andrews NW (2004) Lysosomal fusion is essential for the retention of Trypanosoma cruzi inside host cells. J Exp Med 200: 1135–1143.
[55]  Grab DJ, Garcia-Garcia JC, Nikolskaia OV, Kim YV, Brown A, et al. (2009) Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells. PLoS Negl Trop Dis 3: e479.
[56]  Romano PS, Cueto JA, Casassa AF, Vanrell MC, Gottlieb RA, et al. (2012) Molecular and cellular mechanisms involved in the Trypanosoma cruzi/host cell interplay. IUBMB Life 64: 387–396.
[57]  Reddy A, Caler EV, Andrews NW (2001) Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 106: 157–169.
[58]  Tardieux I, Nathanson MH, Andrews NW (1994) Role in host cell invasion of Trypanosoma cruzi-induced cytosolic-free Ca2+ transients. J Exp Med 179: 1017–1022.
[59]  Woolsey AM, Sunwoo L, Petersen CA, Brachmann SM, Cantley LC, et al. (2003) Novel PI 3-kinase-dependent mechanisms of trypanosome invasion and vacuole maturation. J Cell Sci 116: 3611–3622.
[60]  Rodriguez A, Samoff E, Rioult MG, Chung A, Andrews NW (1996) Host cell invasion by trypanosomes requires lysosomes and microtubule/kinesin-mediated transport. J Cell Biol 134: 349–362.
[61]  Scharfstein J, Andrade D (2011) Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways. Adv Parasitol 76: 101–127.
[62]  Jungmann P, Wilhelmi M, Oberleithner H, Riethmuller C (2008) Bradykinin does not induce gap formation between human endothelial cells. Pflugers Arch 455: 1007–1016.
[63]  Liu LB, Xue YX, Liu YH (2010) Bradykinin increases the permeability of the blood-tumor barrier by the caveolae-mediated transcellular pathway. J Neurooncol 99: 187–194.
[64]  Isshiki M, Ando J, Korenaga R, Kogo H, Fujimoto T, et al. (1998) Endothelial Ca2+ waves preferentially originate at specific loci in caveolin-rich cell edges. Proc Natl Acad Sci U S A 95: 5009–5014.
[65]  Machado FS, Rodriguez NE, Adesse D, Garzoni LR, Esper L, et al. (2012) Recent developments in the interactions between caveolin and pathogens. Adv Exp Med Biol 729: 65–82.
[66]  Park DS, Woodman SE, Schubert W, Cohen AW, Frank PG, et al. (2002) Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am J Pathol 160: 2207–2217.
[67]  Adesse D, Lisanti MP, Spray DC, Machado FS, Meirelles Mde N, et al. (2010) Trypanosoma cruzi infection results in the reduced expression of caveolin-3 in the heart. Cell Cycle 9: 1639–1646.
[68]  Bonney KM, Taylor JM, Daniels MD, Epting CL, Engman DM (2011) Heat-killed Trypanosoma cruzi induces acute cardiac damage and polyantigenic autoimmunity. PLoS One 6: e14571.
[69]  Cunha-Neto E, Bilate AM, Hyland KV, Fonseca SG, Kalil J, et al. (2006) Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry. Autoimmunity 39: 41–54.


comments powered by Disqus